New monoclonal antibodies for non-small-cell lung cancer

Speaker: Lucio Crinò

L. Crino discusses current treatments available for stage IV Squamous cell carcinoma of the lung and elaborates topline results from the REVEL study with docetaxel/ramucirumab in 2nd-line treatment for tumours of non-squamous and squamous histology, as well as the results from phase III study of gemcitabine/cisplatin plus necitumumab in the 1st-line treatment of Squamous cell carcinoma.

Discussion Points

  • What are current treatments available for stage IV squamous NSCLC?
  • What is ramucirumab?
  • Short summary of (topline) findings from the REVEL study
  • What is necitumumab?
  • Short summary of (topline) results of the phase III study with necitumuamb
  • What is the magnitude of benefit?